Evidence map›Paper›PMID 14979918›Full record

ArticleBreast cancer research : BCR2004

Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer.

Vassilios J Papantoniou, Michael A Souvatzoglou, Varvara J Valotassiou, Androniki N Louvrou, Constantina Ambela, John Koutsikos, Dimitrios Lazaris, Julie K Christodoulidou, Maria G Sotiropoulou, Maria J Melissinou and 3 more

Open access · goldAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Breast cancer research : BCR, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Nuclear imaging in cardiac amyloidosis.European journal of nuclear medicine and molecular imaging · 2009
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Vassilios J PapantoniouDepartment of Nuclear Medicine, Alexandra University Hospital, Athens, Greece. vpap@spark.net.gr
Michael A Souvatzoglou
Varvara J Valotassiou
Androniki N Louvrou
Constantina Ambela
John Koutsikos
Dimitrios Lazaris
Julie K Christodoulidou
Maria G Sotiropoulou
Maria J Melissinou
Aris Perperoglou
Spyridon Tsiouris
Cherry J Zerva
Alexandra Hospital · GRIASO General Hospital · GRMetropolitan Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of the present study was to identify the relationships between the uptake of radiotracers - namely pentavalent dimercaptosuccinic acid [(V)DMSA] and sestamibi (MIBI) - and the following parameters in primary breast cancer: steroid receptor concentrations (i.e. estrogen receptor [ER] and progesterone receptor [PR]), Ki-67 expression, tumor size, tumor grade, age, and levels of expression of p53 and c-erbB-2. In addition, by multivariate regression analysis, we further isolated those factors with independent associations with (V)DMSA and/or MIBI uptake in primary breast cancer.

methodsThirty-four patients with histologically confirmed breast carcinoma underwent preoperative scintimammography with technetium-99m (99mTc)-(V)DMSA and/or 99mTc-MIBI in consecutive sessions 10 and 60 min after administration of 925-1110 MBq of each radiotracer. The tumor-to-background ratio was calculated and correlated with the presence of ER, PR, Ki-67, tumor size, tumor grade, p53, and c-erbB-2. ER, PR, p53, and c-erbB-2 were determined immunohistochemically. The analysis included tumor-to-background ratio of (V)DMSA and MIBI uptake as dependent and all of the other parameters as independent variables.

resultsCorrelation was positive between Ki-67 and (V)DMSA (r = 0.37 at 10 min, P = 0.038; r = 0.42 at 60 min, P = 0.018) and inverse between PR and (V)DMSA uptake (r = -0.46 at 10 min, P = 0.010; r = -0.51 at 60 min, P = 0.003). Multivariate regression analysis demonstrated a positive correlation between Ki-67 and (V)DMSA at 60 min (P = 0.045). Ki-67 was not significantly correlated with MIBI uptake, whereas tumor size was positively correlated with MIBI uptake at 60 min both in univariate (r = 0.45, P = 0.027) and multivariate analysis (P = 0.024). Negative correlations were observed between (V)DMSA uptake and ER, as well as between ER/PR and MIBI uptake, but these were not significant.

conclusionKi-67 appears to represent the major independent factor affecting (V)DMSA uptake in breast cancer. Tumor size was the only independent parameter influencing MIBI uptake in breast cancer. (V)DMSA appears to have an advantage over MIBI in that it can be used to visualize tumors with intense proliferative activity, and thus it can identify those tumors that are more aggressive.

Indexed as

Cell ProliferationAdultAgedAged, 80 and overAge FactorsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansKi-67 AntigenMammographyMiddle AgedRadionuclide ImagingReceptors, EstrogenReceptors, ProgesteroneTechnetium Tc 99m Dimercaptosuccinic AcidErb-b2 Receptor Tyrosine KinasesKi-67 AntigenReceptors, EstrogenReceptors, ProgesteroneTechnetium Tc 99m Dimercaptosuccinic AcidTechnetium Tc 99m SestamibiTumor Suppressor Protein p53

Identifiers

PMID14979918
PMCPMC400650
OpenAlexW1494115606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.